Table 1.
Adults adopted BFM regimen.
| Prephase if (TLC > 2.500 cells/mm3 and/or oraganomegaly) | |||
| Vincristine | 2 mg | IV | D1 |
| Dexamethasone | 10 mg/m2 | IV | (D1–7) |
| Phase I induction | |||
| Vincristine | 2 mg | IV | (D1, 8, 15, 22) |
| Doxorubicin | 45 mg/m2 | IV | (D1, 8, 15, 22) |
| L-asparaginase | 5000 u/m2 | IM | (D15–28) |
| Dexamethasone | 10 mg/m2 | IV | 11 days (if patients received prophase 7 days so to complete 4 more days only) |
| Methotrexate | 15 mg | IT | D1 |
| Phase II induction | |||
| Cyclophosphamide | 650 mg/m2 | IV | (D1, 14, 28) |
| Cytarabine | 75 mg/m2 | IV | (D3, 4, 5, 6 and 9, 10, 11, 12 and 16, 17, 18, 19 and 23, 24, 25, 26) |
| Methotrexate | 15 mg | IT | Given as 4 weekly (D1, 8, 15, 22) |
| Cranial prophylaxis | Irradiation (24 Gy) | ||
| Phase I consolidation | |||
| Vincristine | 2 mg | IV | (D1, 8, 15, 22) |
| Doxorubicin | 45 mg/m2 | IV | (D1, 8, 15, 22) |
| Dexamethasone | 10 mg/m2 | IV | For 11 days |
| Phase II consolidation | |||
| Cyclophosphamide | 650 mg/m2 | IV | (D1, 14, 28) |
| Cytarabine | 75 mg/m2 | IV | (D3, 4, 5, 6 and 9, 10, 11, 12 and 16, 17, 18, 19 and 23, 24, 25, 26) |
| Methotrexate | 15 mg | IT | 4 weekly (D1, 8, 15, 22) |
| Maintenance will be given for two years | |||
| 6-Mercaptopurine | 75 mg/m2 | PO | Daily PO |
| Methotrexate | 20 mg/m2 | IV | Once weekly |
| Triple IT cytarabine 40 mg, MTX 15 mg, Dexamethasone 4 mg | Every 2 months till the end of maintenance |
D: Day, Gy: Gray, IT: intrathecal, MTX: Methotrexate, PO: per oral, TLC: total leucocytes count.